SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 563.01 |
| Enterprise Value ($M) | 523.00 |
| Book Value ($M) | 423.77 |
| Book Value / Share | 5.45 |
| Price / Book | 1.33 |
| NCAV ($M) | 408.12 |
| NCAV / Share | 5.25 |
| Price / NCAV | 1.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.45 |
| Return on Assets (ROA) | -0.44 |
| Return on Equity (ROE) | -0.50 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 11.47 |
| Current Ratio | 11.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 463.19 |
| Assets | 478.84 |
| Liabilities | 55.07 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ra Capital Management, L.p. | 5.60 | ||
| 13G/A | Biotechnology Value Fund L P | 5.40 | -42.87 | |
| 13G/A | Paradigm Biocapital Advisors LP | 5.70 | 12.17 | |
| 13G/A | EcoR1 Capital, LLC | 9.99 | 14.47 | |
| 13G/A | Suvretta Capital Management, Llc | 9.99 | 17.18 | |
| 13G/A | Vanguard Group Inc | 5.44 | 18.58 | |
| 13G/A | Flynn James E | 7.15 | 21.46 | |
| 13G/A | BlackRock, Inc. | 9.80 | 41.70 | |
| 13G/A | State Street Corp | 3.93 | -34.29 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 158,538 | 812,283 | 19.52 | |
| 201,770 | 1,366,073 | 14.77 | |
| 353,080 | 1,257,734 | 28.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KPTI – Karyopharm Therapeutics Inc. | KRON – Kronos Bio, Inc. |
| KRYS – Krystal Biotech, Inc. | KYTX – Kyverna Therapeutics, Inc. |
| LVTX – LAVA Therapeutics N.V. |
Financial data and stock pages provided by
Fintel.io